A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Marizomib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- 29 Aug 2018 Planned End Date changed from 1 Jun 2023 to 1 Jul 2023.
- 29 Aug 2018 Planned primary completion date changed from 1 Jun 2022 to 1 Jul 2022.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.